This study is testing a drug called relacorilant with two other medicines, nab-paclitaxel and gemcitabine, for people with a type of cancer called metastatic pancreatic adenocarcinoma (PDAC). PDAC is a severe cancer starting in the pancreas and spreading to other body parts. The study aims to see if this combination is safe and helps patients feel better or live longer. Participants will take relacorilant by mouth, while nab-paclitaxel and gemcitabine will be given through veins on specific days in a 28-day cycle.
- This study involves taking medicine for 3 consecutive days and treatments are given on Days 1, 8, and 15 of each cycle.
- Participants should have a life expectancy of at least 3 months and no prior treatment for metastatic disease.
- Major risks include the possibility of experiencing unmanageable side effects, requiring stopping the study early.
How understandable was the trial content above?
Hard to understand
Easy to understand